# Nuclide record phillip-kuo (person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/people/phillip-kuo/>
  a schema:Person ;
  nuclide:kind "person" ;
  schema:identifier "phillip-kuo" ;
  schema:name "Phillip H. Kuo"@en ;
  schema:description "A nuclear medicine physician who helped write the eligibility scans used to select prostate cancer patients for the VISION trial of lutetium-177 PSMA-617, and who also sets national standards for brain PET scans used in Alzheimer's disease."@en ;
  schema:url <https://nuclide.cc/people/phillip-kuo/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.cityofhope.org/phillip-kuo>, <https://jnm.snmjournals.org/content/63/6/816> ;
  nuclide:tag "PSMA", "theranostics", "brain PET", "clinician" ;
  schema:jobTitle "Professor and Division Chief of Nuclear Medicine and Director of Theranostics, Department of Diagnostic Radiology, City of Hope Cancer Center (since 2024; previously Chief of Nuclear Medicine, University of Arizona, 2014-2024)" ;
  nuclide:related <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/isotopes/lu-177/> .